Similar Outcomes for Robot-Assisted, Radical Prostatectomy

Share this content:
Similar Outcomes for Robot-Assisted, Radical Prostatectomy
Similar Outcomes for Robot-Assisted, Radical Prostatectomy

THURSDAY, July 28, 2016 (HealthDay News) -- For men with newly diagnosed clinically localized prostate cancer, robot-assisted laparoscopic prostatectomy has similar functional outcomes to radical retropubic prostatectomy, according to a study published online July 26 in The Lancet.

John W. Yaxley, M.B.B.S., from the Royal Brisbane & Women's Hospital in Australia, and colleagues conducted a randomized controlled trial involving men with newly diagnosed clinically localized prostate cancer who had chosen surgery as their treatment approach. Men were randomized to robot-assisted laparoscopic prostatectomy or radical retropubic prostatectomy (163 in each group); data were analyzed for 157 and 151 men, respectively. A total of 131 and 121 men, respectively, completed the 12-week questionnaire.

The researchers found that at six and 12 weeks post-surgery, urinary function scores did not differ significantly between the groups (P = 0.09 and 0.48, respectively). Sexual function scores did not differ significantly between the groups at six or 12 weeks (P = 0.45 and 0.18, respectively). The proportions with positive surgical margins were not significantly different in a superiority test (10 percent in the radical retropubic prostatectomy group and 15 percent in the robot-assisted laparoscopic prostatectomy group; P = 0.21).

"Longer term follow-up is needed," the authors write. "In the interim, we encourage patients to choose an experienced surgeon they trust and with whom they have rapport, rather than a specific surgical approach."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths